ArticleWorld journal of gastrointestinal pharmacology and therapeutics2026
Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe therapeutic landscape for unresectable hepatocellular carcinoma (HCC) has evolved with the advent of combinations of immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI). However, the absence of direct comparisons in clinical trials makes it challenging to determine their relative efficacy.
aimTo explore the comparison between ICI and TKI in combination therapy and determine the relative efficacy.
methodsWe conducted a PubMed database search from inception to January 2026, selecting all first-line regimens supported by a randomized controlled trial (RCT). Overall survival (OS) was the endpoint. A series of indirect comparisons was performed across the selected regimens. To conduct our analysis, individual patient data (IPD) were reconstructed from Kaplan-Meier curves. Survival was assessed by the Cox univariate model. Hazard ratio (HR) and restricted mean survival time (RMST) were estimated. Heterogeneity between the sorafenib and lenvatinib control arms was assessed in two separate analyses.
resultsBased on our PubMed search, eight RCTs were included. Most combinations compared with sorafenib significantly improved OS, with camrelizumab plus rivoceranib showing the most favourable HR. This was followed by atezolizumab plus bevacizumab, tremelimumab plus durvalumab, toripalimab plus bevacizumab and anlotinib plus penpulimab. Cabozantinib plus atezolizumab did not demonstrate a clear benefit. Camrelizumab plus rivoceranib was superior to tremelimumab plus durvalumab (HR = 0.78; 95%CI: 0.61-0.99) and anlotinib plus penpulimab (HR = 0.73; 95%CI: 0.57-0.93). Compared with lenvatinib, nivolumab plus ipilimumab and pembrolizumab plus lenvatinib yielded modest improvements, with no significant difference between the two. RMST analyses suggested that nivolumab plus ipilimumab, lenvatinib and pembrolizumab plus lenvatinib produced similar results to those of camrelizumab plus rivoceranib. The choice of comparator meaningfully shapes the estimated treatment effect.
conclusionOur study compared the efficacy of the main first-line treatments recommended for unresectable HCC. While we were able to rank the magnitude of efficacy across these treatments, the intrinsic limitations of our methods (primarily the reconstruction of IPD and the indirect nature of the treatment comparisons) should be borne in mind.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.